Dyspareunia is a common symptom of vulvar and vaginal atrophy, which often occurs in women who have already undergone menopause.
Intrarosa, developed by Queben, Canada-based Endoceutics, is a once-daily vaginal insert.
The product represents the first FDA-approved treatment to contain the active ingredient prasterone, according to a press release on the agency’s website.
More articles on supply chain:
Gavis Pharma earns FDA approval for generic painkiller
Amazon sues sellers for allegedly bogus products
Study: Generic heart drugs vary widely in price, limit access to uninsured patients
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
